FMP

FMP

Enter

RGNX - REGENXBIO Inc.

photo-url-https://images.financialmodelingprep.com/symbol/RGNX.png

REGENXBIO Inc.

RGNX

NASDAQ

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

5.89 USD

0.48 (8.15%)

RGNX Financial Statements

Year

2024

2023

2022

2021

Total Revenue

83.33M

90.24M

112.72M

470.35M

Cost of Revenue

33.57M

37.21M

54.55M

51.83M

Gross Profit

49.76M

53.03M

58.18M

418.51M

Operating Expenses

283.11M

321.16M

321.06M

258.53M

Research and Development

208.52M

232.27M

242.45M

181.44M

Selling, General & Administrative Expenses

76.62M

88.49M

85.28M

79.33M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

76.62M

88.49M

85.28M

79.33M

Other Expenses

-2.03M

397k

-6.68M

-2.24M

Operating Income

-233.35M

-268.13M

-262.88M

159.98M

Total Other Income/Expenses Net

6.24M

4.48M

-17.53M

-18.73M

Income Before Tax

-227.1M

-263.65M

-280.4M

141.25M

Income Tax

0

-152k

-84k

13.41M

Net Income

-227.1M

-263.49M

-280.32M

127.84M

Basic EPS

-4.59

-6.02

-6.5

3.01

EPS Diluted

-4.59

-6.02

-6.5

2.91

Basic Average Shares

49.51M

43.73M

43.15M

42.44M

Diluted Average Shares

49.51M

43.73M

43.15M

43.91M

EBITDA

-198.23M

-239.46M

-244.24M

169.54M

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep